At Clasp Therapeutics, we are expanding the reach of immuno-oncology with novel precision medicines that enable the immune system to identify and specifically destroy hard-to-treat tumors bearing common driver mutations, regardless of tumor type. This approach enables a highly selective paradigm where every patient has the opportunity to respond to treatment.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/05/24 | $150,000,000 | Series A |
Alexandria Venture Investments Blackbird Ventures BrightEdge Fund Catalio Capital Cure Ventures Novo Holdings Pictet Third Rock Ventures Vivo Capital | undisclosed |
